DXCM vs. TNDM

Last updated Apr 1, 2026

Compare and contrast key facts about DexCom, Inc. (DXCM) and Tandem Diabetes Care, Inc. (TNDM).

Performance

DXCM vs. TNDM - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in DexCom, Inc. (DXCM) and Tandem Diabetes Care, Inc. (TNDM). The values are adjusted to include any dividend payments, if applicable.

DXCM vs. TNDM - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
DXCM DexCom, Inc.	-5.38%	-14.66%	-37.33%	9.58%	-15.64%	45.23%	69.02%	82.59%	108.75%	-3.87%
TNDM Tandem Diabetes Care, Inc.	-12.78%	-38.98%	21.77%	-34.19%	-70.14%	57.32%	60.51%	56.99%	1,508.90%	-89.02%

Fundamentals

Market Cap DXCM : $25.05B TNDM : $1.30B
EPS DXCM : $2.07 TNDM : -$3.03
PS Ratio DXCM : 5.45 TNDM : 1.28
PB Ratio DXCM : 9.12 TNDM : 8.40
Total Revenue (TTM) DXCM : $4.66B TNDM : $1.01B
Gross Profit (TTM) DXCM : $2.80B TNDM : $546.01M
EBITDA (TTM) DXCM : $1.34B TNDM : -$173.04M

Returns By Period

In the year-to-date period, DXCM achieves a -5.38% return, which is significantly higher than TNDM's -12.78% return. Over the past 10 years, DXCM has outperformed TNDM with an annualized return of 14.02%, while TNDM has yielded a comparatively lower -14.33% annualized return.

DXCM

• 1D: 1.45%
• 1M: -14.48%
• YTD: -5.38%
• 6M: -6.67%
• 1Y: -8.04%
• 3Y*: -18.54%
• 5Y*: -7.23%
• 10Y*: 14.02%

TNDM

• 1D: -2.12%
• 1M: -24.23%
• YTD: -12.78%
• 6M: 57.91%
• 1Y: 0.05%
• 3Y*: -22.14%
• 5Y*: -26.21%
• 10Y*: -14.33%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

DXCM vs. TNDM — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

DXCM

DXCM Risk / Return Rank: 34
DXCM Sharpe Ratio Rank: 34
DXCM Sortino Ratio Rank: 31
DXCM Omega Ratio Rank: 32
DXCM Calmar Ratio Rank: 37
DXCM Martin Ratio Rank: 37

TNDM

TNDM Risk / Return Rank: 43
TNDM Sharpe Ratio Rank: 41
TNDM Sortino Ratio Rank: 46
TNDM Omega Ratio Rank: 44
TNDM Calmar Ratio Rank: 42
TNDM Martin Ratio Rank: 41

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

DXCM vs. TNDM - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for DexCom, Inc. (DXCM) and Tandem Diabetes Care, Inc. (TNDM). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	DXCM	TNDM	Difference
Sharpe ratio Return per unit of total volatility	-0.18	0.00	-0.19
Sortino ratio Return per unit of downside risk	0.04	0.62	-0.59
Omega ratio Gain probability vs. loss probability	1.01	1.07	-0.07
Calmar ratio Return relative to maximum drawdown	-0.19	-0.01	-0.18
Martin ratio Return relative to average drawdown	-0.38	-0.02	-0.36
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

DXCM vs. TNDM - Sharpe Ratio Comparison

The current DXCM Sharpe Ratio is -0.18, which is lower than the TNDM Sharpe Ratio of 0.00. The chart below compares the historical Sharpe Ratios of DXCM and TNDM, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	DXCM	TNDM	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.18	0.00	-0.19
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.16	-0.40	+0.24
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.29	-0.19	+0.48
Sharpe Ratio (All Time) Calculated using the full available price history	0.29	-0.23	+0.52

Correlation

The correlation between DXCM and TNDM is 0.43, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.

Dividends

DXCM vs. TNDM - Dividend Comparison

Neither DXCM nor TNDM has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

DXCM vs. TNDM - Drawdown Comparison

The maximum DXCM drawdown since its inception was -94.61%, roughly equal to the maximum TNDM drawdown of -99.25%. Use the drawdown chart below to compare losses from any high point for DXCM and TNDM.

Drawdown Indicators

	DXCM	TNDM	Difference
Max Drawdown Largest peak-to-trough decline	-94.61%	-99.25%	+4.64%
Max Drawdown (1Y) Largest decline over 1 year	-38.75%	-56.99%	+18.24%
Max Drawdown (5Y) Largest decline over 5 years	-66.32%	-93.40%	+27.08%
Max Drawdown (10Y) Largest decline over 10 years	-66.32%	-97.99%	+31.67%
Current Drawdown Current decline from peak	-61.43%	-93.61%	+32.18%
Average Drawdown Average peak-to-trough decline	-35.79%	-76.93%	+41.14%
Ulcer Index Depth and duration of drawdowns from previous peaks	19.27%	27.59%	-8.32%

Volatility

DXCM vs. TNDM - Volatility Comparison

The current volatility for DexCom, Inc. (DXCM) is 9.22%, while Tandem Diabetes Care, Inc. (TNDM) has a volatility of 20.72%. This indicates that DXCM experiences smaller price fluctuations and is considered to be less risky than TNDM based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	DXCM	TNDM	Difference
Volatility (1M) Calculated over the trailing 1-month period	9.22%	20.72%	-11.50%
Volatility (6M) Calculated over the trailing 6-month period	27.63%	54.98%	-27.35%
Volatility (1Y) Calculated over the trailing 1-year period	43.67%	76.28%	-32.61%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	46.76%	65.93%	-19.17%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	48.31%	77.52%	-29.21%

Financials

DXCM vs. TNDM - Profitability Comparison

The chart below illustrates the profitability comparison between DexCom, Inc. and Tandem Diabetes Care, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

DXCM - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, DexCom, Inc. reported a gross profit of 792.70M and revenue of 1.26B. Therefore, the gross margin over that period was 62.9%.

TNDM - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Tandem Diabetes Care, Inc. reported a gross profit of 167.46M and revenue of 290.38M. Therefore, the gross margin over that period was 57.7%.

DXCM - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, DexCom, Inc. reported an operating income of 323.00M and revenue of 1.26B, resulting in an operating margin of 25.6%.

TNDM - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Tandem Diabetes Care, Inc. reported an operating income of 8.29M and revenue of 290.38M, resulting in an operating margin of 2.9%.

DXCM - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, DexCom, Inc. reported a net income of 267.30M and revenue of 1.26B, resulting in a net margin of 21.2%.

TNDM - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Tandem Diabetes Care, Inc. reported a net income of -589.00K and revenue of 290.38M, resulting in a net margin of -0.2%.